Increased intracranial pressure is a life-threatening condition requiring immediate recognition and management. Normal ICP in adults is 5–15 mm Hg; sustained values >20–22 mm Hg are pathologic and warrant treatment. [1-2] The Monro-Kellie doctrine dictates that the cranial vault is a fixed space — any increase in brain, blood, or CSF volume must be compensated or ICP rises exponentially. [1][3]
The following figure illustrates normal vs. pathological intracranial pressure dynamics, herniation patterns, and ICP monitoring:
1. History
- Headache character: Worst in the morning, progressive, worsened by Valsalva maneuvers (coughing, straining, bending forward) [4]
- Associated symptoms: Nausea/vomiting (often projectile), transient visual obscurations, diplopia (horizontal), pulsatile tinnitus, neck/back pain [4-5]
- Timing: Acute (trauma, hemorrhage) vs. subacute/chronic (tumor, IIH, hydrocephalus)
- Triggers: Recent head trauma, recent weight gain, new medications (tetracyclines, retinoids), pregnancy/postpartum
- Important negatives: Absence of fever (argues against meningitis), no thunderclap onset (argues against SAH), no focal weakness at onset
2. Alarm Features
- Cushing triad: Hypertension, bradycardia, irregular respirations — a late and ominous sign of impending herniation [2][6-7]
- Unilateral fixed, dilated pupil — suggests uncal herniation with CN III compression [7-8]
- Rapid GCS decline (drop ≥2 points), posturing (decorticate/decerebrate) [7]
- Papilledema — bilateral disc edema on fundoscopy; prompts urgent workup for life-threatening causes [9]
- New focal neurologic deficits, seizures, encephalopathy, or coma [10]
- Sixth nerve palsy (false localizing sign from diffuse ICP elevation) [5]
3. Medications
Medications that can CAUSE elevated ICP: [5][11-12]
- Strongly associated: Vitamin A derivatives/retinoids (isotretinoin), tetracycline-class antibiotics (minocycline, doxycycline), recombinant growth hormone, lithium
- Moderately associated: Corticosteroid withdrawal
- Weakly associated: Cyclosporine, fluoroquinolones, danazol, valproic acid
Medications used to TREAT elevated ICP
- Hyperosmolar therapy (first-line):
- Mannitol 20%: 0.25–1 g/kg IV bolus; avoid if hypotensive (osmotic diuresis) [1][3]
- Hypertonic saline 3%: 2–5 mL/kg bolus over 10–20 min; 23.4% HTS 30 mL via central line for refractory ICP [13-14]
- Acetazolamide 500–1000 mg BID (for IIH — reduces CSF production) [15-16]
- Sedation/analgesia: Propofol, midazolam, fentanyl for ventilated patients [3]
- Barbiturates: Pentobarbital for refractory ICP (last-tier; risk of cardiac depression and hypotension) [3][13]
- Dexamethasone: Effective for vasogenic edema (tumors, abscesses); NOT effective for cytotoxic edema (TBI, stroke) [17]
Contraindicated/caution
- Avoid nifedipine, chlorpromazine, reserpine in elevated ICP — can raise ICP and decrease cerebral perfusion pressure [18]
- Avoid prophylactic hyperventilation to PaCO₂ <30 mm Hg [13]
4. Diet
- IIH: Weight loss is a cornerstone of treatment; even 5–10% body weight reduction can significantly lower ICP [5][15]
- Sodium management: Monitor closely with hypertonic saline use; avoid rapid sodium shifts (risk of central pontine myelinolysis) [19]
- Acute setting: NPO if surgical intervention anticipated
- Avoid excessive vitamin A intake (supplements, liver, cod liver oil) [11-12]
5. Review of Systems
- Neuro: Headache quality/timing, vision changes (blurring, transient obscurations, diplopia), tinnitus, cognitive changes, seizures, weakness
- Ophthalmologic: Visual field loss, photophobia
- ENT: Rhinorrhea (CSF leak), hearing changes, serous otitis media [5]
- Systemic: Fever (infection), weight changes, medication use
- Cardiopulmonary: Dyspnea (pulmonary hypertension as rare cause), sleep apnea symptoms [20]
6. Collateral History and Family History
- Collateral: Witnessed trauma, duration of altered consciousness, seizure activity, baseline mental status, medication list, substance use
- Family history: Intracranial aneurysms (SAH risk), coagulopathies, neurofibromatosis, tuberous sclerosis (associated CNS tumors)
- Social context: Anticoagulant use, alcohol use (fall risk, coagulopathy), recent travel (infectious etiologies)
7. Risk Factors
- Traumatic: TBI (falls, MVCs, assaults) — most common acute cause
- IIH: Obesity (BMI >30), female sex, childbearing age, recent weight gain [5][15]
- Vascular: Hypercoagulable states (OCP use, pregnancy, malignancy) → cerebral venous thrombosis [10]
- Infectious: Immunosuppression (HIV, transplant) → meningitis, abscess
- Neoplastic: Known malignancy with metastatic potential
- Hydrocephalus: Prior neurosurgery, intraventricular hemorrhage, meningitis
- Medications: Tetracyclines, retinoids, growth hormone, lithium, corticosteroid withdrawal [11]
8. Differential Diagnosis
- Intracranial mass lesion: Tumor, abscess, subdural empyema [9][20]
- Intracranial hemorrhage: Epidural, subdural, intracerebral, subarachnoid [9]
- Hydrocephalus: Obstructive or communicating; VP shunt malfunction
- Cerebral venous sinus thrombosis — headache, seizures, focal deficits; diagnose with MRV [10]
- Meningitis/encephalitis — fever, meningismus, altered mental status
- Idiopathic intracranial hypertension (IIH) — obese woman of childbearing age, papilledema, normal imaging [5][15]
- Hypertensive encephalopathy — severely elevated BP with encephalopathy
- Carbon monoxide poisoning — toxic brain edema [20]
Cannot-miss mimics: Posterior fossa mass (rapid herniation risk), dural AV fistula, carcinomatous meningitis
9. Past Medical History
- Prior TBI, neurosurgery, VP shunt placement
- Known intracranial neoplasm or systemic malignancy
- History of IIH or prior LP with elevated opening pressure
- Coagulopathy or anticoagulant/antiplatelet use
- Chronic conditions: Obesity, sleep apnea, pulmonary hypertension, right heart failure [20]
- Autoimmune/inflammatory conditions (sarcoidosis, lupus)
10. Physical Exam
Vital signs
- Cushing triad: Hypertension + bradycardia + irregular respirations (late sign) [2][6]
- Fever → consider infectious etiology
Neurologic exam
- GCS assessment — document E/V/M components; GCS ≤8 = severe brain injury [21]
- Pupils: Unilateral fixed dilated pupil (uncal herniation); bilateral fixed dilated (brainstem compression). Sensitivity of pupillary dilation for elevated ICP: 28%, specificity: 86% [8]
- Fundoscopy: Papilledema (blurred disc margins, venous engorgement, loss of spontaneous venous pulsations) [4][9]
- CN VI palsy: Lateral rectus weakness (false localizing sign)
- Motor exam: Posturing (decorticate = flexion; decerebrate = extension), lateralizing signs
- Head/scalp: Lacerations, Battle sign, raccoon eyes, hemotympanum (basilar skull fracture)
11. Lab Studies
- CBC, CMP, coagulation studies (PT/INR, PTT) — baseline; coagulopathy assessment
- Blood gas — monitor PaCO₂ if ventilated (target 35–40 mm Hg; avoid <30 mm Hg) [13][22]
- Serum osmolality — monitor during osmotherapy (hold mannitol if >320 mOsm/L; hold HTS if Na >160 mEq/L) [13]
- Blood cultures, lactate — if infectious etiology suspected
- CSF analysis (if LP performed after imaging): Opening pressure (≥250 mm H₂O suggests elevated ICP), cell count, protein, glucose, culture, cytology [4][20]
- ESR/CRP — if giant cell arteritis or inflammatory process suspected
- Toxicology screen — if poisoning suspected (CO levels, drug screen)
12. Imaging
First-line
- Non-contrast CT head — rapid, widely available; identifies hemorrhage, mass lesions, hydrocephalus, midline shift, cisternal compression [4][20]
Gold standard / advanced
- MRI brain with contrast + MRV — preferred for IIH workup, cerebral venous thrombosis, meningeal processes, posterior fossa lesions [9][16]
When imaging is unnecessary
13. Special Tests
- Point-of-care ocular ultrasound: Optic nerve sheath diameter (ONSD) >5 mm suggests elevated ICP; AUROC 0.94 for detecting ICP ≥20 mm Hg [4][8][25]
- Invasive ICP monitoring — gold standard; external ventricular drain (EVD) preferred (diagnostic + therapeutic via CSF drainage) [21]
- Transcranial Doppler (TCD): Pulsatility index — poor performance for detecting elevated ICP (AUROC 0.55–0.72); not recommended as sole diagnostic tool [8]
- Lumbar puncture with opening pressure: Essential for IIH diagnosis (≥250 mm H₂O); only after imaging excludes mass lesion/hydrocephalus [4][20]
- Quantitative pupillometry: More reliable than clinical assessment for tracking pupillary reactivity trends [21]
14. ECG
- ECG is not a primary diagnostic tool for elevated ICP but should be obtained to:
- Identify bradycardia as part of Cushing reflex [6]
- Rule out cardiac arrhythmias in the setting of hemodynamic instability
- Detect neurogenic ECG changes (ST changes, T-wave inversions, QT prolongation) seen with SAH or severe brain injury
15. Assessment
Severity stratification
- Mild elevation (20–25 mm Hg): May respond to general measures (head elevation, sedation, normothermia)
- Moderate elevation (25–40 mm Hg): Requires active osmotherapy and close monitoring
- Severe/refractory (>40 mm Hg): Requires escalation to second-tier therapies (barbiturates, decompressive craniectomy) [2-3]
Typical presentation: Progressive headache (worse in AM), nausea/vomiting, visual changes, papilledema [4-5]
Atypical presentations: Isolated sixth nerve palsy, CSF rhinorrhea, behavioral changes in children, acute decompensation without warning in posterior fossa lesions
Complications: Herniation syndromes (uncal, central, tonsillar, upward), permanent visual loss, brain death [3][26]
16. Treatment Plan
Tier 0 — General measures: [2-3][22]
- Head of bed elevated 30°, head midline, avoid neck vein compression
- Maintain normothermia (treat fever aggressively)
- Ensure adequate sedation/analgesia in intubated patients
- Avoid hypotension (MAP goal to maintain CPP ≥60 mm Hg in adults)
- Correct hypoxia, hypercapnia, hyponatremia
- Seizure prophylaxis if indicated
Tier 1 — First-line therapies: [2-3][27]
- CSF drainage via EVD if available
- Hyperosmolar therapy:
- Mannitol 20%: 0.25–1 g/kg IV bolus (monitor serum osmolality <320)
- 3% HTS: 150–250 mL bolus (or 2–5 mL/kg); target Na <160
- Moderate hyperventilation (PaCO₂ 30–35 mm Hg) — brief bridge only
Tier 2 — Second-line therapies: [2-3][13]
- Moderate hypothermia (32–33°C)
- High-dose barbiturate therapy (pentobarbital) — only if hemodynamically stable
- 23.4% HTS 30 mL via central line for refractory episodes [13]
Tier 3 — Surgical: [13][27]
- Decompressive craniectomy for refractory ICP despite maximal medical therapy
- Surgical evacuation of mass lesions (hematoma, abscess, tumor)
IIH-specific treatment: [5][15-16]
- Weight loss (target ≥5–10% body weight)
- Acetazolamide 500–1000 mg BID (titrate up to 4 g/day)
- Therapeutic LP with CSF removal for acute visual threat
- Surgical options: Optic nerve sheath fenestration, VP/LP shunt, venous sinus stenting
17. Disposition
Admit (ICU) if
- GCS ≤8 or declining neurologic exam [21]
- Acute structural cause requiring monitoring or surgery (hemorrhage, mass, hydrocephalus)
- Cushing triad, herniation signs, or need for ICP monitoring
- Refractory ICP requiring osmotherapy or ventilator management
Admit (floor/observation) if
- New papilledema with visual threat requiring urgent workup
- New diagnosis of IIH with significant visual field loss
- Cerebral venous thrombosis requiring anticoagulation initiation
Discharge considerations
- Stable IIH with mild symptoms, no visual threat, and reliable follow-up
- Must have ophthalmology and neurology follow-up arranged
Neurosurgery consultation triggers: [21]
- Surgical mass lesion (epidural/subdural hematoma, tumor, abscess)
- Hydrocephalus requiring EVD or shunt
- GCS ≤8 with structural brain damage on CT
- Refractory ICP despite medical management
- Need for decompressive craniectomy
18. Follow Up / Return Precautions
Follow-up timing
- IIH: Ophthalmology within 1–2 weeks for visual field testing and OCT; neurology within 2–4 weeks [5][16]
- Post-surgical: Neurosurgery follow-up within 1–2 weeks
- Post-TBI: Serial imaging and clinical reassessment per institutional protocol
Return precautions — instruct patients to return immediately for:
- Worsening or thunderclap headache
- New vision loss, double vision, or visual field changes
- Vomiting that cannot be controlled
- New weakness, numbness, difficulty speaking, or seizures
- Altered consciousness or confusion
- Clear fluid draining from nose or ears (CSF leak)
Expected recovery
- IIH: Gradual improvement over weeks to months with weight loss and acetazolamide; headache may persist even after ICP normalizes [5][15]
- Post-traumatic: Variable; depends on injury severity and secondary insults
- Post-surgical (tumor/hematoma): Depends on underlying pathology and extent of resection
References
1. Guidelines for the Management of Severe TBI, 4th Edition. — Nancy Carney, Annette M. Totten, Cindy O'Reilly, et al Brain Trauma Foundation (2016). 2016.
2. Intracranial Pressure Monitoring in Adult Patients With Traumatic Brain Injury: Challenges and Innovations. — Zoerle T, Beqiri E, Åkerlund CAI, et al. The Lancet. Neurology. 2024.
3. Traumatic Intracranial Hypertension. — Stocchetti N, Maas AI. The New England Journal of Medicine. 2014.
4. A Review of the Clinical Presentation, Causes, and Diagnostic Evaluation of Increased Intracranial Pressure in the Emergency Department. — Olaru C, Langberg S, McCoin NS. The Western Journal of Emergency Medicine. 2024.
5. Idiopathic Intracranial Hypertension. — Horton JC. The New England Journal of Medicine. 2025.
6. History of the Cushing Reflex. — Fodstad H, Kelly PJ, Buchfelder M. Neurosurgery. 2006.
7. Prehospital Guidelines for the Management of Traumatic Brain Injury - 3rd Edition. — Lulla A, Lumba-Brown A, Totten AM, et al. Prehospital Emergency Care. 2023.
8. Diagnosis of Elevated Intracranial Pressure in Critically Ill Adults: Systematic Review and Meta-Analysis. — Fernando SM, Tran A, Cheng W, et al. BMJ. 2019.
9. Diagnosis and Clinical Features of Common Optic Neuropathies. — Biousse V, Newman NJ. The Lancet. Neurology. 2016.
10. Diagnosis and Management of Cerebral Venous Thrombosis: A Scientific Statement From the American Heart Association. — Saposnik G, Bushnell C, Coutinho JM, et al. Stroke. 2024.
11. Drug-Induced Intracranial Hypertension: A Systematic Review and Critical Assessment of Drug-Induced Causes. — Tan MG, Worley B, Kim WB, Ten Hove M, Beecker J. American Journal of Clinical Dermatology. 2020.
12. Idiopathic Intracranial Hypertension. — Ball AK, Clarke CE. The Lancet. Neurology. 2006.
13. Abusive Head Trauma in Infants and Children: Technical Report. — Narang SK, Haney S, Duhaime AC, et al. Pediatrics. 2025.
14. Hypertonic Saline Versus Other Intracranial Pressure-Lowering Agents for People With Acute Traumatic Brain Injury. — Chen H, Song Z, Dennis JA. The Cochrane Database of Systematic Reviews. 2020.
15. Diagnosis and Management of Headache: A Review. — Robbins MS. The Journal of the American Medical Association. 2021.
16. Papilledema: A Review of Etiology, Pathophysiology, Diagnosis, and Management. — Xie JS, Donaldson L, Margolin E. Survey of Ophthalmology. 2021.
17. Clinical Pharmacokinetic Considerations in the Treatment of Increased Intracranial Pressure. — Heinemeyer G. Clinical Pharmacokinetics. 1987.
18. Treatment of Systemic Hypertension and Intracranial Hypertension in Cases of Brain Hemorrhage. — Hayashi M, Kobayashi H, Kawano H, Handa Y, Hirose S. Stroke. 1988.
19. Equimolar Doses of Hypertonic Agents (Saline or Mannitol) in the Treatment of Intracranial Hypertension After Severe Traumatic Brain Injury. — Huang X, Yang L, Ye J, He S, Wang B. Medicine. 2020.
20. Headache Arising From Idiopathic Changes in CSF Pressure. — Ducros A, Biousse V. The Lancet. Neurology. 2015.
21. Best Practices In The Management Of Traumatic Brain Injury. — Geoffrey T. Manley MD PhD, Gregory W. Albert MD MPH FAANS FACS FAAP, Gretchen M. Brophy PharmD BCPS FCCP FCCM FNCS MCCM, et al American College of Surgeons (2024). 2024.
22. Early Management of Isolated Severe Traumatic Brain Injury Patients in a Hospital Without Neurosurgical Capabilities: A Consensus and Clinical Recommendations of the World Society of Emergency Surgery (WSES). — Picetti E, Catena F, Abu-Zidan F, et al. World Journal of Emergency Surgery : WJES. 2023.
23. Brain MRI and Ophthalmic Biomarkers of Intracranial Pressure. — D'Antona L, Asif H, Craven CL, et al. Neurology. 2021.
24. Novel and Classic Imaging Signs of Increased Intracranial Pressure. — Berhanu D, Martins G, Antunes AP, et al. Neuroradiology. 2025.
25. The Diagnostic Accuracy of Noninvasive Methods to Measure the Intracranial Pressure: A Systematic Review and Meta-Analysis. — Sallam A, Abdelaal Ahmed Mahmoud M Alkhatip A, Kamel MG, et al. Anesthesia and Analgesia. 2021.
26. Brain Herniation and Intracranial Hypertension. — Tadevosyan A, Kornbluth J. Neurologic Clinics. 2021.
27. Decompressive Craniectomy for the Treatment of High Intracranial Pressure in Closed Traumatic Brain Injury. — Sahuquillo J, Dennis JA. The Cochrane Database of Systematic Reviews. 2019.